Skip to content

ACRO BIOMEDICAL CO., LTD.: 10-K filed 2021-04-02

What ACRO BIOMEDICAL CO., LTD. reported in its annual report filed 2021-04-02 (fiscal FY 2020): 25 published measures, 80 facts as tagged in accession 0001640334-21-000767.

This filing

Form
10-K (annual report)
Filed
2021-04-02
Fiscal period
fiscal FY 2020
Accession
0001640334-21-000767 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ACRO BIOMEDICAL CO., LTD. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-12-31998,053USD
At 2019-12-31932,126USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-12-31312,185USD
At 2019-12-31133,887USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-12-31685,868USD
At 2019-12-31798,239USD
At 2019-09-30873,672USD
At 2018-12-311,167,860USD
At 2018-09-301,242,154USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-12-3118,123USD
At 2019-12-31911USD
At 2019-09-301,472USD
At 2018-12-3137,607USD
At 2018-09-301,148USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-117,453USD366
2019-10-01 to 2019-12-31-75,873USD92
2019-01-01 to 2019-12-31-371,604USD365
2018-10-01 to 2018-12-31-75,016USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-199,460USD366
2019-10-01 to 2019-12-3134,928USD92
2019-01-01 to 2019-12-31-59,709USD365
2018-10-01 to 2018-12-31174,329USD92

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-12-31216,672USD366
2019-10-01 to 2019-12-31-35,489USD92
2019-01-01 to 2019-12-3123,013USD365
2018-10-01 to 2018-12-31-137,870USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-12-31-238,654USD
At 2019-12-31-121,201USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-18,092USD366
2019-10-01 to 2019-12-310USD92
2019-01-01 to 2019-12-31-53,130USD365
2018-10-01 to 2018-12-31-19,941USD92

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-01-01 to 2019-12-31148,395USD365
2018-10-01 to 2018-12-31151,694USD92

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-130,463USD366
2019-10-01 to 2019-12-31-75,433USD92
2019-01-01 to 2019-12-31-422,751USD365
2018-10-01 to 2018-12-31-94,235USD92

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-12-31973,353USD
At 2019-12-31879,471USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-12-31312,185USD
At 2019-12-31111,541USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2020-01-01 to 2020-12-31289,867USD366
2019-10-01 to 2019-12-3187,529USD92
2019-01-01 to 2019-12-31434,847USD365
2018-10-01 to 2018-12-31229,635USD92

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2020-12-31938,000USD
At 2019-12-31878,560USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-01-01 to 2020-12-31159,404USD366
2019-10-01 to 2019-12-3112,096USD92
2019-01-01 to 2019-12-3112,096USD365
2018-10-01 to 2018-12-31135,400USD92

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-01-01 to 2020-12-31528,560USD366
2019-10-01 to 2019-12-31181,440USD92
2019-01-01 to 2019-12-31181,440USD365
2018-10-01 to 2018-12-311,218,600USD92

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2020-01-01 to 2020-12-31289,867USD366
2019-10-01 to 2019-12-3187,529USD92
2019-01-01 to 2019-12-31434,847USD365
2018-10-01 to 2018-12-31229,635USD92

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-12-3147,760,000shares
At 2019-12-3147,760,000shares

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-12-3124,700USD
At 2019-12-3148,425USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2020-12-3124,500USD
At 2019-12-3146,310USD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2020-12-310USD
At 2019-12-310USD

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2020-01-01 to 2020-12-31-5,082USD366
2019-10-01 to 2019-12-31-440USD92
2019-01-01 to 2019-12-31-1,983USD365
2018-10-01 to 2018-12-31-722USD92

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-12-310USD366
2019-10-01 to 2019-12-310USD92
2019-01-01 to 2019-12-310USD365
2018-10-01 to 2018-12-310USD92

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-12-3159,440USD366
2019-10-01 to 2019-12-31-181,440USD92
2019-01-01 to 2019-12-31-181,440USD365
2018-10-01 to 2018-12-31-86,600USD92

Inspect the source

Entity
ACRO BIOMEDICAL CO., LTD. / CIK 0001622996
Captured
2026-09-19T11:19:47.057Z
SEC response SHA-256
b3abbbd950a9b9c0ba03d5604cc52c43ddb41d59ea263147bca632d90b36b6c9

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001622996.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))